Evidence map›Paper›PMID 35061722›Full record

ArticlePloS one2022

Lives saved and lost in the first six month of the US COVID-19 pandemic: A retrospective cost-benefit analysis.

Olga Yakusheva, Eline van den Broek-Altenburg, Gayle Brekke, Adam Atherly

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Policy analysis and data mining tools for controlling COVID-19 policies.Network modeling and analysis in health informatics and bioinformatics · 2023
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Olga YakushevaDepartment of Systems, Populations and Leadership, School of Nursing, University of Michigan, Ann Arbor, MI, United States of America.ORCID 0000-0001-5501-1397
Eline van den Broek-AltenburgLarner College of Medicine, University of Vermont, Burlington, VT, United States of America.
Gayle BrekkeUniversity of Kansas Medical Center, Kansas City, KS, United States of America.
Adam AtherlyLarner College of Medicine, University of Vermont, Burlington, VT, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the beginning of the COVID-19 US epidemic in March 2020, sweeping lockdowns and other aggressive measures were put in place and retained in many states until end of August of 2020; the ensuing economic downturn has led many to question the wisdom of the early COVID-19 policy measures in the US. This study's objective was to evaluate the cost and benefit of the US COVID-19-mitigating policy intervention during the first six month of the pandemic in terms of COVID-19 mortality potentially averted, versus mortality potentially attributable to the economic downturn. We conducted a synthesis-based retrospective cost-benefit analysis of the full complex of US federal, state, and local COVID-19-mitigating measures, including lockdowns and all other COVID-19-mitigating measures, against the counterfactual scenario involving no public health intervention. We derived parameter estimates from a rapid review and synthesis of recent epidemiologic studies and economic literature on regulation-attributable mortality. According to our estimates, the policy intervention saved 866,350-1,711,150 lives (4,886,214-9,650,886 quality-adjusted life-years), while mortality attributable to the economic downturn was 57,922-245,055 lives (2,093,811-8,858,444 life-years). We conclude that the number of lives saved by the spring-summer lockdowns and other COVID-19-mitigation was greater than the number of lives potentially lost due to the economic downturn. However, the net impact on quality-adjusted life expectancy is ambiguous.

Indexed as

Models, StatisticalQuality-Adjusted Life YearsCommunicable Disease ControlCost-Benefit AnalysisCOVID-19HumansPublic HealthQuality of LifeQuarantineRetrospective StudiesSARS-CoV-2United States

Identifiers

PMID35061722
PMCPMC8782469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.